92 studies found for:    Open Studies | "Waldenstrom Macroglobulinemia"
Show Display Options
Rank Status Study
1 Unknown  Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
Conditions: Waldenström Macroglobulinemia;   Lymphoplasmacytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Drug: Chlorambucil;   Drug: Fludarabine
2 Recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
3 Recruiting Randomised Trial in Waldenstrom's Macroglobulinaemia
Condition: Waldenstrom's Macroglobulinaemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Fludarabine
4 Recruiting An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia (WM)
Intervention: Drug: ACP-196
5 Not yet recruiting Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Ixazomib;   Drug: Dexamethasone;   Drug: Rituximab
6 Recruiting Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
7 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
8 Recruiting Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Bortezomib-Rituximab-Bendamustine
9 Recruiting Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: IMO-8400
10 Recruiting Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Dexamethasone, Rituximab, Cyclophosphamide;   Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
11 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
12 Recruiting Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention:
13 Recruiting Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Conditions: Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention: Drug: oprozomib
14 Recruiting A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Conditions: Indolent B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
Intervention: Drug: DI-B4
15 Recruiting Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Conditions: Non-Hodgkin's Lymphoma (NHL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia (WM);   Diffuse Large B-cell Lymphoma (DLBCL),;   Other B-cell NHL Subtypes, Including WM;   T-cell NHL
Intervention: Drug: CB-839
16 Unknown  Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia
Condition: Lymphoma
Intervention: Procedure: leukapheresis
17 Recruiting Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Intraocular Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Drug: Romidepsin
18 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
19 Recruiting Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Lymphoma;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Biological: Therapeutic Autologous Lymphocytes
20 Recruiting Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Conditions: Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Aggressive Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large B -Cell Lymphoma;   Childhood Immunoblastic Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Adult T-Cell Leukemia/Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Mantle Cell Lymphoma;   Refractory Plasma Cell Myeloma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Natural Killer Cell Therapy;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years